GILD Gilead Sciences, Inc. Stock Quote

GILD [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	17.67	EPS (ttm)	3.58	Insider Own	0.10%	Shs Outstand	1.25B	Perf Week	1.26%
Market Cap	79.50B	Forward P/E	9.95	EPS next Y	6.36	Insider Trans	-1.60%	Shs Float	1.25B	Perf Month	-0.52%
Income	4.51B	PEG	-	EPS next Q	1.53	Inst Own	83.90%	Short Float	1.33%	Perf Quarter	3.23%
Sales	27.47B	P/S	2.89	EPS this Y	14.00%	Inst Trans	0.79%	Short Ratio	1.69	Perf Half Y	-6.21%
Book/sh	15.88	P/B	3.98	EPS next Y	-3.18%	ROA	6.80%	Target Price	69.52	Perf Year	-8.77%
Cash/sh	4.24	P/C	14.93	EPS next 5Y	-1.35%	ROE	22.00%	52W Range	57.19 - 74.12	Perf YTD	-12.86%
Dividend	2.92	P/FCF	12.58	EPS past 5Y	-13.10%	ROI	16.40%	52W High	-14.69%	Beta	0.35
Dividend %	4.62%	Quick Ratio	1.30	Sales past 5Y	-2.10%	Gross Margin	75.70%	52W Low	10.57%	ATR	1.28
Employees	14400	Current Ratio	1.50	Sales Q/Q	2.60%	Oper. Margin	26.30%	RSI (14)	58.71	Volatility	1.70% 2.21%
Optionable	Yes	Debt/Eq	1.32	EPS Q/Q	-98.90%	Profit Margin	16.40%	Rel Volume	0.53	Prev Close	63.27
Shortable	Yes	LT Debt/Eq	1.26	Earnings	Apr 28 AMC	Payout	79.50%	Avg Volume	9.89M	Price	63.23
Recom	2.40	SMA20	2.38%	SMA50	3.90%	SMA200	-5.04%	Volume	1,131,390	Change	-0.06%

Feb-28-22

Downgrade

BMO Capital Markets

Outperform → Market Perform

$75 → $65

Feb-02-22

Reiterated

Wells Fargo

Equal Weight

$72 → $70

Feb-02-22

Reiterated

Truist

Hold

$77 → $75

Feb-02-22

Reiterated

RBC Capital Mkts

Outperform

$87 → $85

Feb-02-22

Reiterated

BofA Securities

Neutral

$73 → $71

Feb-02-22

Reiterated

BMO Capital Markets

Outperform

$85 → $75

Jan-28-22

Upgrade

Argus

Hold → Buy

Jan-06-22

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$84 → $74

Dec-09-21

Resumed

Wells Fargo

Equal Weight

$72

Dec-06-21

Initiated

Goldman

Neutral

$80

Nov-19-21

Upgrade

BMO Capital Markets

Market Perform → Outperform

$72 → $85

Nov-19-21

Resumed

Piper Sandler

Neutral

$77

Oct-20-21

Resumed

Cowen

Outperform

Jul-30-21

Reiterated

RBC Capital Mkts

Outperform

$81 → $84

Jul-30-21

Reiterated

BMO Capital Markets

Market Perform

$67 → $72

Apr-01-21

Upgrade

Bernstein

Mkt Perform → Outperform

$80

Mar-30-21

Upgrade

Redburn

Neutral → Buy

Jan-19-21

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$83

Jan-04-21

Upgrade

Guggenheim

Neutral → Buy

Nov-03-20

Resumed

Morgan Stanley

Equal-Weight

$67

May-20-22 10:01AM	Gilead at Forefront of Herculean Effort to Combat COVID-19 News Direct
May-19-22 01:30PM	Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report Business Wire
03:00AM	Gilead Stock Earns Rating Upgrade After Quick Turnaround Investor's Business Daily
May-18-22 11:41AM	Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates Zacks
08:46AM	Living with Metastatic Bladder Cancer: Joey's Journey News Direct
May-17-22 04:30PM	Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting Business Wire
11:42AM	Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection Benzinga
11:30AM	Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold Zacks
May-16-22 04:10PM	FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV Business Wire
May-13-22 01:44PM	Stock rebound uncertain for U.S. biotechs as risks multiply for investors American City Business Journals
10:50AM	Did Gilead Sciences, Inc. (NASDAQ:GILD) Use Debt To Deliver Its ROE Of 23%? Simply Wall St.
10:45AM	Gilead Sciences Stock Trying To Close In On Key Technical Benchmark Investor's Business Daily
09:57AM	Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV News Direct
May-12-22 04:04PM	Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis Investor's Business Daily
May-11-22 01:42PM	Goldman Sachs likes these 3 top dividend stocks yielding as high as 7.6% in a manic market, locking down a growing income stream makes sense MoneyWise
01:05PM	15 Best Income Stocks To Invest In Insider Monkey
08:46AM	Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies News Direct
May-08-22 07:05AM	Is Gilead Sciences Too Dependent On These 2 Areas of Its Business? Motley Fool
May-06-22 09:26AM	Closing the Representation Gap in Schools, One Black Male Teacher at a Time News Direct
May-04-22 06:48PM	Pfizer: The Treasure of Albert Bourla InvestorPlace
01:39PM	Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News Zacks
May-03-22 09:30AM	Here's how Apple, Alphabet, Meta, Netflix and 21 other Bay Area companies' stocks fared in April American City Business Journals
08:46AM	Opinion: The Road to Ending Visceral Leishmaniasis News Direct
May-02-22 08:30AM	Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation Business Wire
Apr-29-22 03:45PM	11 Companies Making Headlines Following Earnings Reports Insider Monkey
01:57PM	Why These Analysts Are Bullish On Gilead's Q1 Earnings Benzinga
11:05AM	Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales Zacks
09:26AM	On Earth Day, Gilead Marks Strides in Environmental Sustainability News Direct
02:00AM	Gilead Sciences (GILD) Q1 2022 Earnings Call Transcript Motley Fool
Apr-28-22 05:25PM	Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates Zacks
05:19PM	Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion Investor's Business Daily
04:43PM	UPDATE 2-Gilead earnings beat Street estimates, writedown taken on cancer drug Reuters
04:25PM	Gilead earnings beat Street estimates, writedown taken on cancer drug Reuters
04:02PM	Gilead Sciences Announces First Quarter 2022 Financial Results Business Wire
Apr-27-22 02:03PM	Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More Zacks
12:44PM	Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News Zacks
10:26AM	CDC study highlights speed with which omicron variant infected Americans, and WHO warns testing is still crucial MarketWatch
08:38AM	Should You Buy Gilead (GILD) Ahead of Earnings? Zacks
Apr-26-22 06:13PM	Gilead Sciences to Present at Upcoming Investor Conferences Business Wire
05:59PM	J&J sues to block sales of 'dangerous' counterfeit HIV drugs Reuters
11:15AM	Healthcare ETFs in Focus Ahead of Q1 Earnings Zacks
09:26AM	Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program News Direct
07:27AM	Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients Benzinga
06:15AM	7 Dividend Stocks Paying Over 5% to Buy Now InvestorPlace
Apr-25-22 02:29PM	Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19 Business Wire
02:20PM	UPDATE 1-U.S. FDA approves Gilead's COVID-19 drug for young children Reuters
02:20PM	FDA formally approves Gilead's Veklury for young children MarketWatch
11:49AM	Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards? Zacks
09:02AM	Glaxo (GSK) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-24-22 06:05PM	Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19 Business Wire
Apr-21-22 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
03:01PM	Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
11:13AM	NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy Benzinga
Apr-20-22 11:31AM	6 Defensive Healthcare Stocks With Big Dividend Yields Barrons.com
08:46AM	Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey News Direct
Apr-19-22 10:57AM	Shareholders push for review of lobbying by Gilead, other drugmakers American City Business Journals
08:00AM	Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland Business Wire
Apr-18-22 09:26AM	The Translatinx Network Helps a Resilient Community 'Live Its Truth' News Direct
Apr-15-22 09:57AM	Tour for Diversity in Medicine, Gilead Sciences and the Advisory Group to SHC Vaccine Equity Program to Receive Booker T. Washington Award From National Minority Quality Forum News Direct
Apr-14-22 04:05PM	Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022 Business Wire
01:34PM	Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More Zacks
Apr-13-22 05:50PM	Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
09:26AM	Four Questions With Anu Osinusi: Gilead's Commitment to People Living With Viral Hepatitis News Direct
08:14AM	Why Sierra Oncology Stock Is Soaring Today Motley Fool
Apr-12-22 11:20AM	Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed Zacks
08:49AM	RBC: the FDA lifting the hold on Gilead's experimental cancer therapy is a 'much-need piece of good news' MarketWatch
Apr-11-22 04:07PM	FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies Business Wire
Apr-08-22 11:32AM	The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals Zacks
Apr-07-22 01:23PM	Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More Zacks
11:13AM	How Gilead built a more-diverse, relatively younger board American City Business Journals
Apr-06-22 10:26AM	At the Forefront of HIV Health and Healing in Spain: Ferran's Story News Direct
09:46AM	Is it a Wise Decision to Invest in Gilead Sciences (GILD)? Insider Monkey
Apr-05-22 05:50PM	Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
05:30PM	Gilead's CEO gets pay bump as cancer drug strategy hits snags American City Business Journals
Apr-01-22 06:48PM	UPDATE 1-U.S. FDA approves Gilead cell therapy for earlier lymphoma Reuters
06:01PM	Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL) Business Wire
05:49PM	U.S. FDA approves Gilead cell therapy for earlier lymphoma Reuters
10:26AM	Advocating for Black Women With Triple-Negative Breast Cancer: Ricki's Story News Direct
Mar-31-22 11:23AM	VIR Stock Gains on News of Inclusion in the S&P SmallCap 600 Zacks
Mar-30-22 05:50PM	Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
10:32AM	Claflin University's Deeply Rooted Commitment to Social Justice News Direct
Mar-28-22 11:00AM	Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere Business Wire
Mar-25-22 10:31AM	Channeling Her Passion to Spread Awareness About TNBC: LaToya's Journey News Direct
Mar-23-22 10:53AM	2 High-Yielding Stocks Trading Near Multiyear Lows Motley Fool
Mar-22-22 05:50PM	Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
10:31AM	Opinion: Searching for the Next Generation of Sustainable Health Care News Direct
Mar-21-22 10:04AM	Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains? Zacks
Mar-18-22 10:34AM	An Open Letter on Ukraine From Daniel O'Day, Chairman & CEO News Direct
Mar-16-22 05:45PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
Mar-15-22 10:31AM	Opinion: Why Corporate Philanthropy Must Stand Against Stigma News Direct
Mar-11-22 05:50PM	Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Mar-10-22 12:27PM	The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences Zacks
10:31AM	Opinion: Building an Inclusive World Through Sports, Art, and Culture News Direct
08:20AM	Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To US$0.73 Simply Wall St.
Mar-09-22 05:29PM	Gilead to cut 114 jobs in New Jersey but add office space there, manufacturing in SoCal American City Business Journals
12:54PM	Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates Zacks
Mar-08-22 04:14PM	Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal Zacks
10:31AM	Congratulations to Taiyin Yang, EVP, for Being Elected to the 2022 Class of the National Academy of Engineering. News Direct
Mar-07-22 04:07PM	Gilead Sciences Dives As Investors Question Its Latest Cancer Buyout Investor's Business Daily
08:30AM	Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer Business Wire

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lofton Kevin E	Director	Apr 28	Option Exercise	25.62	16,322	418,251	90,525	Apr 29 06:43 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 11	Sale	58.24	3,634	211,644	32,576	Mar 14 09:46 PM
Wilfong Diane E.	SVP, Controller & CAO	Mar 10	Option Exercise	0.00	3,297	0	27,516	Mar 14 09:30 PM
Mercier Johanna	Chief Commercial Officer	Mar 10	Option Exercise	0.00	6,987	0	37,765	Mar 14 09:14 PM
O'Day Daniel Patrick	Chairman & CEO	Mar 10	Option Exercise	0.00	24,003	0	260,396	Mar 14 09:52 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 09	Sale	63.89	1,691	108,038	32,576	Feb 11 02:57 PM
Dickinson Andrew D	Chief Financial Officer	Feb 06	Option Exercise	0.00	1,817	0	60,473	Feb 08 08:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Option Exercise	0.00	2,727	0	35,303	Feb 08 08:24 PM
Wilfong Diane E.	SVP, Controller & CAO	Feb 06	Option Exercise	0.00	1,864	0	24,739	Feb 08 08:22 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 01	Sale	68.54	14,061	963,682	32,576	Feb 02 06:37 PM
Wilfong Diane E.	SVP, Controller & CAO	Aug 17	Option Exercise	68.08	13,610	926,536	34,008	Aug 18 07:32 PM
Wilfong Diane E.	SVP, Controller & CAO	Aug 17	Sale	72.50	13,610	986,725	20,398	Aug 18 07:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience